올리고뉴클레오티드 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global oligonucleotide CDMO market size is expected to reach USD 20.60 Billion in 2034 from USD 3.45 Billion in 2025, growing at a CAGR of 21.96 during 2026-2034.This market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of oligonucleotide-based therapeutics. Contract development and manufacturing organizations provide specialized expertise, advanced production capabilities, and regulatory support that accelerate drug development timelines. Rising investments in precision medicine, genetic therapies, and nucleic acid-based treatments are significantly driving market expansion. Continuous advancements in manufacturing technologies are improving production quality and scalability.

Growing demand for RNA therapeutics, antisense oligonucleotides, and gene-silencing technologies is a major factor supporting industry growth. Pharmaceutical companies are partnering with specialized CDMOs to access high-quality manufacturing infrastructure while reducing operational costs and accelerating commercialization. Increasing research activities, expanding clinical pipelines, and favorable regulatory developments are creating strong business opportunities. Technological improvements in synthesis, purification, and quality control continue strengthening manufacturing capabilities.

Future prospects remain exceptionally promising as genetic medicine and personalized therapeutics continue advancing. Expanding investments in biotechnology research, advanced manufacturing facilities, and innovative therapeutic platforms will generate sustained demand for CDMO services. Artificial intelligence, automation, and digital manufacturing technologies are expected to improve production efficiency and regulatory compliance. Continued innovation and strategic collaborations will support long-term growth across the global oligonucleotide CDMO market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Service Type

• Contract Manufacturing (Clinical Stage, Commercial Stage)
• Contract Development
• Analytical and Quality Control Services
• Regulatory and CMC Support Services

By Oligonucleotide Type

• Antisense Oligonucleotides
• Small Interfering RNA
• Guide RNA
• Aptamers
• Other Oligonucleotide Types

By Application

• Therapeutic Applications (Rare Diseases, Oncology, Neurology, Cardiometabolic Diseases, Infectious Diseases)
• Research Applications
• Diagnostic Applications
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Diagnostic Companies
• Academic & Research Institutes
• Gene Therapy & Cell Therapy Developers
• Other End Users

COMPANIES PROFILED

• Agilent Technologies Inc., Ajinomoto Co. Inc., Almac Group Limited, Asymchem Laboratories (Tianjin) Co. Ltd., Bachem Holding AG, BioSpring GmbH, CordenPharma International, Curia Global Inc., EUROAPI S.A., Eurofins Scientific SE, GenScript Biotech Corporation, Kaneka Corporation, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, PolyPeptide Group AG, ST Pharm Co. Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Contract Manufacturing (Clinical Stage, Commercial Stage) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Analytical and Quality Control Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Regulatory and CMC Support Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY OLIGONUCLEOTIDE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Oligonucleotide Type
• 5.2. Antisense Oligonucleotides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Small Interfering RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Guide RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Aptamers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Oligonucleotide Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Therapeutic Applications (Rare Diseases, Oncology, Neurology, Cardiometabolic Diseases, Infectious Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Diagnostic Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Gene Therapy & Cell Therapy Developers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Service Type
  • 8.2.2 By Oligonucleotide Type
  • 8.2.3 By Application
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Service Type
  • 8.3.2 By Oligonucleotide Type
  • 8.3.3 By Application
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Service Type
  • 8.4.2 By Oligonucleotide Type
  • 8.4.3 By Application
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Service Type
  • 8.5.2 By Oligonucleotide Type
  • 8.5.3 By Application
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Service Type
  • 8.6.2 By Oligonucleotide Type
  • 8.6.3 By Application
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL OLIGONUCLEOTIDE CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Agilent Technologies Inc
  • 10.2.2 Ajinomoto Co. Inc
  • 10.2.3 Almac Group Limited
  • 10.2.4 Asymchem Laboratories (Tianjin) Co. Ltd
  • 10.2.5 Bachem Holding AG
  • 10.2.6 BioSpring GmbH
  • 10.2.7 CordenPharma International
  • 10.2.8 Curia Global Inc
  • 10.2.9 EUROAPI S.A
  • 10.2.10 Eurofins Scientific SE
  • 10.2.11 GenScript Biotech Corporation
  • 10.2.12 Kaneka Corporation
  • 10.2.13 Lonza Group Ltd
  • 10.2.14 Maravai LifeSciences Holdings Inc
  • 10.2.15 Merck KGaA
  • 10.2.16 PolyPeptide Group AG
  • 10.2.17 ST Pharm Co. Ltd
  • 10.2.18 Syngene International Limited
  • 10.2.19 Thermo Fisher Scientific Inc
  • 10.2.20 WuXi AppTec Co. Ltd